What You Should Know:
– xlayer, the leading cloud-based platform powering an end-to-end direct-to-patient (DTP) healthcare experience, announced availability of a Complete Blood Count (CBC) test with at-home sample collection. This move supports biopharma partners who want to accelerate virtual care and reduce barriers to care for patients.
– Available through ixEngage, ixlayer’s DTP biopharma solution, biopharma companies can develop programs to include a CBC test, speciality and PCP telehealth consultations and prescription delivery. Top U.S. biopharma companies have already signed on to implement ixEngage’s remote CBC testing, with plans to make their programs publicly available as early as Q1 2025.
Streamlining Patient-Centered Healthcare: ixEngage by ixlayer
ixlayer is the leading provider of cloud-based platforms, delivering a seamless, end-to-end direct-to-patient healthcare experience. The brand’s name symbolizes its core strengths: “i” represents a robust data and technology infrastructure, while “x” highlights its exceptional user experience. ixEngage, ixlayer’s proprietary platform, connects biopharma with patients and seamlessly integrates with all healthcare ecosystem partners. This technology accelerates diagnosis, supports optimal care, enhances operational efficiency, and improves health equity and outcomes for all.
Remote complete blood count (CBC) testing offers unparalleled accessibility to vital healthcare services traditionally available only in clinical settings. Using cutting-edge, easy-to-administer blood collection kits, patients can now collect samples from the comfort of their homes. The advanced technology within ixEngage ensures secure data transmission of lab results between patients and healthcare providers. Additionally, this digital care connection allows patients to receive timely feedback from physicians on CBC results and treatment options, driving patient-centered care initiatives.
This capability simplifies the prescribing process for essential medications, including biologics, by enabling remote CBC testing, a prerequisite for many treatments. It eliminates the need for in-person lab visits, allowing patients and physicians to access test results more quickly, which shortens the path to treatment. CBC testing is critical for diagnosing and managing conditions such as asthma, autoimmune diseases, cancer, chronic kidney disease, and heart disease. With ixEngage, biopharma can deliver a streamlined, data-driven patient journey that leads to faster treatment decisions and improved outcomes.
Approximately 70% of clinical decisions depend on lab testing, yet traditional methods result in 40% of blood lab prescriptions going unfulfilled. By removing bottlenecks in lab appointment scheduling, ixEngage’s remote CBC testing feature ensures that patients can more easily access essential diagnostics, reducing delays and enhancing the overall healthcare experience. A recent survey revealed that 83% of U.S. physicians believe at-home testing accelerates diagnoses and improves health outcomes, further underscoring the value of ixEngage’s integrated approach.
“With the ability to collect at-home CBC samples, patients will now have more convenient access to life-saving diagnostics, care and treatment,” said Dr. Bernard Esquivel, MD and PhD, Chief Medical Officer at ixlayer. “This advancement can allow physicians regular insight to a patient’s biomarkers resulting in personalized treatment plans, reducing hospitalizations, and ensuring timely interventions, particularly for those with limited access to healthcare facilities.”
